department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Lerochol · pharmadog

pharmadog
drugs
Lerochol

drug

patient view →

lerodalcibep

Marketedupdated 2mo ago

by LIB Therapeutics LLC

Approved

community read0 votes

all catalysts(1)

approval · 1

LEROCHOL (LERODALCIBEP-LIGA) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Lerochol

generic

lerodalcibep-liga

MOA

12.1 Mechanism of Action Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep-liga increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels. [see Clinical Pharmacology ( 12.3 )] .

indication

Homozygous Familial Hypercholesterolemia (HoFH)

phase

marketed

$TGTX55.25+3.64%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 3

tagApproval4 co-mentions · 1 sources
drugLEROCHOL4 co-mentions · 1 sources
companyLIB Therapeutics LLC2 co-mentions · 1 sources

Trials studying lerodalcibep

phase3Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHnot yet recruitingn=150
phase3A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemiarecruitingn=210
phase3Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patientscompletedn=166
phase3Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reductionenrolling by invitationn=2,000
phase3Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reductionunknownn=900
phase3Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reductioncompletedn=478
phase3Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reductionunknownn=900